These divergent responses to PGE2 are probably due to differing levels of intracellular lipid components, since Gdpd3−/− CML stem cells alter their production of several LPAs and lipid mediators, leading to the activation of the downstream AKT/mTORC1 pathway. This evidence concerns the gene GDPD3 and chronic myelogenous leukemia, BCR-ABL1 positive.